The Protein and Contrast Agent–Specific Influence of Pathological Plasma-Protein Concentration Levels on Contrast-Enhanced Magnetic Resonance Imaging
Authors:
- Johannes M. FroehlichJFJohannes M. Froehlich
- Natalie C. ChuckNCNatalie C. Chuck
- Raffaele CurcioRCRaffaele Curcio
- Val M. RungeVRVal M. Runge
- Gustav AndreisekGAGustav Andreisek
- Daniel NanzDNDaniel Nanz
- Andreas BossABAndreas Boss
- 1 September 2014
- journal article
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 49 (9) , 608-619
Abstract
The objective of this study was to measure the protein-specific response of r1 and r2 relaxivities of commercially available gadolinium-based magnetic resonance imaging contrast agents to variation of plasma-protein concentrations. In this in vitro study, contrast agent (gadofosveset trisodium, gadoxetate disodium, gadobutrol, and gadoterate meglumine) dilution series (0-2.5 mmol Gd/L) were prepared with plasma-protein (human serum albumin [HSA] and immunoglobulin G [IgG]) concentrations at physiological (42 and 10 g/L HSA and IgG, respectively, Normal) and at 3 pathological levels with HSA/IgG concentrations of 10/10 (solution Alb low), 42/50 (IgG mild), and 42/70 (IgG severe) g/L. Contrast-agent molar relaxivities and relaxivity-enhancing protein-contrast-agent interaction coefficients were determined on the basis of inversion-recovery and spin-echo data acquired at 1.5 and 3.0 T at 37°C. Protein-induced magnetic resonance imaging signal changes were calculated. The effective r1 and r2 molar relaxivities consistently increased with albumin and IgG concentrations. At 1.5 T, the r1 values increased by 10.2 (gadofosveset), 4.3 (gadoxetate), 1.3 (gadobutrol), and 1.1 L s mmol (gadoterate), respectively, from the Alb low to the IgG severe solution. At 3.0 T, the r1 values increased by 2.9 (gadofosveset), 2.3 (gadoxetate), 0.7 (gadobutrol), and 0.9 (gadoterate) L s mmol, respectively. An excess of IgG most strongly increased the r1 of gadoxetate (+40 and +19% at 1.5 and 3.0 T, respectively, from Normal to IgG severe). An albumin deficiency most strongly decreased the r1 of gadofosveset (-44% and -20% at 1.5 and 3.0 T, respectively, from Normal to Alb low). The modeling confirmed a strong gadofosveset r1 enhancement by albumin and suggested stronger IgG than albumin effects on the apparent molar relaxivity of the other agents per protein mass concentration at 1.5 T. Pathological deviations from normal plasma-protein concentrations in aqueous solutions result in changes of effective r1 and r2 contrast-agent relaxivities and projected signal enhancements that depend on the contrast agent, the blood-serum protein profile, and the field strength.Keywords
This publication has 21 references indexed in Scilit:
- Clinical impact of serum proteins on drug deliveryJournal of Controlled Release, 2012
- Recent advances in macromolecular hydrodynamic modelingMethods, 2011
- Gadolinium-Based Magnetic Resonance Contrast Agents at 7 TeslaInvestigative Radiology, 2010
- Evidence for weak protein binding of commercial extracellular gadolinium contrast agentsMagnetic Resonance in Medicine, 2010
- Serum Protein Electrophoresis: An Underused but Very Useful TestDigestion, 2009
- Comprehensive investigation of the non-covalent binding of MRI contrast agents with human serum albuminJBIC Journal of Biological Inorganic Chemistry, 2007
- Influence of Human Serum Albumin on Longitudinal and Transverse Relaxation Rates (R1 and R2) of Magnetic Resonance Contrast AgentsInvestigative Radiology, 2006
- T1, T2 relaxation and magnetization transfer in tissue at 3TMagnetic Resonance in Medicine, 2005
- Albumin-bound MRI contrast agents: the dilemma of the rotational correlation timeMagnetic Resonance Materials in Physics, Biology and Medicine, 2001
- Targeted relaxation enhancement agents for MRIMagnetic Resonance in Medicine, 1991